XML 39 R22.htm IDEA: XBRL DOCUMENT
v3.24.0.1

Loss Per Common Share | 12 Months Ended
--- | ---
Dec. 31, 2023
Earnings Per Share [Abstract] |
Loss Per Common Share | Loss Per Common Share The following table sets forth the computation of basic and diluted earnings per share available for common stockholders (in thousands, except per share data):
|  |  | For the Year Ended December 31,
|  |  |  |  | 2023 |  | 2022 |  | 2021
Loss from continuing operations |  |  |  |  | $ | (113,040) |  |  | $ | (18,701) |  |  | $ | (30,284) |
Loss from discontinued operations, net of tax |  |  |  |  | — |  |  | (463) |  |  | (7,317) |
Loss before preferred dividends and accretion of Series A Preferred Stock |  |  |  |  | (113,040) |  |  | (19,164) |  |  | (37,601) |
Dividends and accretion of Series A Preferred Stock |  |  |  |  | (29,220) |  |  | — |  |  | — |
Net loss attributable to common shareholders of Evolent Health, Inc. |  |  |  |  | $ | (142,260) |  |  | $ | (19,164) |  |  | $ | (37,601) |
Weighted-average common shares outstanding - basic and diluted |  |  |  |  | 111,251 |  |  | 93,699 |  |  | 86,067 |
Loss per common share |  |  |  |  |  |  |  |  |
Basic and diluted: |  |  |  |  |  |  |  |  |
Continuing operations |  |  |  |  | $ | (1.28) |  |  | $ | (0.20) |  |  | $ | (0.35) |
Discontinued operations |  |  |  |  | — |  |  | — |  |  | (0.09) |
Basic and diluted loss per share attributable to common shareholders of Evolent Health, Inc. |  |  |  |  | $ | (1.28) |  |  | $ | (0.20) |  |  | $ | (0.44) |
Basic net loss per common share is calculated using the weighted average number of common shares outstanding during the period. Diluted net earnings per common share, if any, gives effect to diluted stock options (calculated based on the treasury stock method), shares issuable upon debt conversion (calculated using an as-if converted method). Anti-dilutive shares excluded from the calculation of weighted-average common shares presented above are presented below (in thousands):
|  |  | For the Year Ended December 31,
|  |  |  |  | 2023 |  | 2022 |  | 2021
Restricted stock units ("RSUs"), performance-based RSUs (“PSUs”) and leveraged stock units ("LSUs") |  |  |  |  | 1,352 |  |  | 1,804 |  |  | 1,807 |
Stock options |  |  |  |  | 794 |  |  | 1,769 |  |  | 2,036 |
Series A Preferred Stock |  |  |  |  | 4,375 |  |  | — |  |  | — |
Convertible senior notes |  |  |  |  | 6,808 |  |  | 9,574 |  |  | 12,602 |
Total |  |  |  |  | 13,329 |  |  | 13,147 |  |  | 16,445 |

X
- References No definition available. + Details
Name: | us-gaap_EarningsPerShareAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for earnings per share. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//260/tableOfContent Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-3 + Details
Name: | us-gaap_EarningsPerShareTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration